[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 173,077
  • Shares Outstanding, K 189,279
  • Annual Sales, $ 154,900 K
  • Annual Income, $ -20,200 K
  • EBIT $ -3 M
  • EBITDA $ 0 M
  • 60-Month Beta 1.70
  • Price/Sales 1.18
  • Price/Cash Flow N/A
  • Price/Book 22.49
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.04 on 05/11/26
  • Next Earnings Date 08/14/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 114.55% (-79.17%)
  • Historical Volatility 100.47%
  • IV Percentile 24%
  • IV Rank 8.63%
  • IV High 805.14% on 03/13/26
  • IV Low 49.33% on 03/26/26
  • Expected Move (DTE 34) 0.2550 (27.95%)
  • Put/Call Vol Ratio 1.04
  • Today's Volume 57
  • Volume Avg (30-Day) 441
  • Put/Call OI Ratio 1.17
  • Today's Open Interest 42,733
  • Open Int (30-Day) 39,986
  • Expected Range 0.6574 to 1.1674

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 2
  • High Estimate $-0.01
  • Low Estimate $-0.02
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9000 +1.38%
on 05/11/26
1.3400 -31.91%
on 05/06/26
-0.0247 (-2.64%)
since 04/14/26
3-Month
0.7362 +23.93%
on 03/30/26
1.3400 -31.91%
on 05/06/26
-0.2376 (-20.66%)
since 02/13/26
52-Week
0.7362 +23.93%
on 03/30/26
2.3000 -60.33%
on 07/02/25
-0.8076 (-46.95%)
since 05/14/25

Most Recent Stories

More News
Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum...

HRTX : 0.9124 (-0.22%)
Heron Therapeutics: Q1 Earnings Snapshot

Heron Therapeutics: Q1 Earnings Snapshot

HRTX : 0.9124 (-0.22%)
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) Q1 2026 total net revenue of $34.7 million Reached settlement...

HRTX : 0.9124 (-0.22%)
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will...

HRTX : 0.9124 (-0.22%)
Heron Therapeutics: Q4 Earnings Snapshot

Heron Therapeutics: Q4 Earnings Snapshot

HRTX : 0.9124 (-0.22%)
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Achieved $154.9 Million in 2025 Net Revenue – Issues Full-Year 2026 Net Revenue Guidance...

HRTX : 0.9124 (-0.22%)
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will...

HRTX : 0.9124 (-0.22%)
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited...

HRTX : 0.9124 (-0.22%)
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker...

HRTX : 0.9124 (-0.22%)
Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics: Q3 Earnings Snapshot

HRTX : 0.9124 (-0.22%)

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

3rd Resistance Point 0.9608
2nd Resistance Point 0.9493
1st Resistance Point 0.9309
Last Price 0.9124
1st Support Level 0.9010
2nd Support Level 0.8895
3rd Support Level 0.8711

See More

52-Week High 2.3000
Fibonacci 61.8% 1.7026
Fibonacci 50% 1.5181
Fibonacci 38.2% 1.3336
Last Price 0.9124
52-Week Low 0.7362

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.